Registry for Chronic Obstructive Pulmonary Disease With Pulmonary Hypertension in China
The Prevalence, Disease Course, Prognosis and Interaction of Chronic Obstructive Pulmonary Disease With Pulmonary Hypertension
1 other identifier
observational
1,708
1 country
1
Brief Summary
Pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD). It is reported that over half of COPD patients develop pulmonary hypertension. COPD and pulmonary hypertension may have pathological or genetics interactions so that patients having both disorders tend to have poor prognosis. Echocardiography is widely used to detect pulmonary hypertension, but it's not accurate enough. Therefore, high-quality data reflecting the prevalence, disease course and outcome of pulmonary hypertension in COPD is very limited in China. The aim of the study is to detect pulmonary hypertension with right heart catheterization, describe its outcome in Chinese COPD patients and explore the underlying interaction mechanism.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2017
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 10, 2017
CompletedFirst Posted
Study publicly available on registry
June 14, 2017
CompletedStudy Start
First participant enrolled
June 15, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2020
CompletedJune 14, 2017
June 1, 2017
3.5 years
June 10, 2017
June 13, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
COPD exacerbations
total hospitalizations times due to COPD exacerbations
3 years
Secondary Outcomes (4)
modified British medical research council (mMRC) score
3 years
COPD Assessment Test (CAT) score
3 years
6 minutes walk distance
3 years
transplant-free survival rate
3 years
Eligibility Criteria
Stable COPD patients
You may qualify if:
- Stable chronic obstructive pulmonary disease (COPD) patients
You may not qualify if:
- Patients with other serious respiratory diseases
- Patients with pulmonary hypertension other than group 3
- Patients with right heart hypertrophy or dysfunction not caused by chronic obstructive pulmonary diseases
- Patients with limited life expectancy
- Patients with history of tracheal intubation or stoke, acute coronary syndrome in 6 months
- Psychopath or addict
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
Biospecimen
serum and blood cells
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief of Pulmonary Vascular Disease Center
Study Record Dates
First Submitted
June 10, 2017
First Posted
June 14, 2017
Study Start
June 15, 2017
Primary Completion
December 31, 2020
Study Completion
December 31, 2020
Last Updated
June 14, 2017
Record last verified: 2017-06